펩타이드 항생제 시장 비즈니스 기회, 성장요인, 업계 동향 분석 및 예측(2026-2035년)

The Global Peptide Antibiotics Market generated USD 5.4 billion in 2025 and is estimated to grow at a CAGR of 5.2% to reach USD 8.9 billion by 2035.

Growth across the peptide antibiotic industry is strongly influenced by increasing concerns regarding antimicrobial resistance and the urgent need for new treatment approaches capable of combating drug-resistant infections. Financial support from public institutions as well as independent organizations is playing a significant role in accelerating innovation within this field. Investment programs aimed at discovering advanced antimicrobial solutions are encouraging the development of new peptide-based therapeutic options. At the same time, rapid progress in peptide synthesis technologies and modern drug delivery platforms is expanding the development pipeline for peptide antibiotics. These advancements are enabling researchers to design more effective antimicrobial agents that can address emerging resistance challenges. As healthcare providers continue seeking targeted therapies capable of delivering reliable outcomes, peptide antibiotics are gaining greater attention within pharmaceutical research and clinical treatment programs, strengthening the long-term growth outlook for the peptide antibiotics market.

Technological progress in bioengineering and pharmaceutical formulation has significantly enhanced the therapeutic performance of peptide antibiotics by improving their stability, bioavailability, and treatment efficiency. The increasing focus on targeted medical treatments is also encouraging the development of peptide-based antimicrobial therapies, as these compounds can be engineered to attack resistant microbial strains while minimizing unwanted systemic effects. Peptide antibiotics, commonly referred to as antimicrobial peptides, consist of short chains of amino acids capable of disrupting microbial survival processes. These molecules inhibit microbial growth by interfering with essential cellular mechanisms and structural components. Such peptides may originate naturally within biological systems or be produced synthetically through laboratory-based development methods.

The non-ribosomal synthesized peptide antibiotics segment generated USD 4 billion in 2025. This segment maintains a leading position because of its broad antimicrobial activity and strong resistance to enzymatic degradation. Non-ribosomal peptide antibiotics are generated through specialized enzyme complexes that allow extensive structural diversity and the incorporation of uncommon amino acid components. This structural flexibility improves the therapeutic strength and durability of these antibiotics, making them particularly valuable for addressing infections caused by multidrug-resistant bacterial strains.

The skin infection segment held 33.6% share in 2025. The segment's strong presence within the peptide antibiotics industry is associated with the growing occurrence of bacterial skin-related conditions and the rising need for effective therapeutic solutions. The increasing incidence of persistent wounds and infection-related complications following medical procedures has also contributed to higher demand for peptide-based antibiotics. These medications are often selected because they provide targeted antimicrobial activity while reducing the likelihood of broader systemic side effects.

North America Peptide Antibiotics Market accounted for 40.5% share in 2025. The region's leadership within the global peptide antibiotics industry is supported by advanced pharmaceutical research capabilities, strong regulatory oversight, and significant healthcare spending. A well-established biotechnology and pharmaceutical sector further encourages innovation in antibiotic drug development. In addition, government-backed research funding programs and policy initiatives designed to promote the discovery of new antimicrobial therapies are helping accelerate development and commercialization activities across the region.

Key companies operating in the Global Peptide Antibiotics Market include Pfizer, Merck, Sanofi, GSK plc, Eli Lilly and Company, AbbVie, Teva Pharmaceuticals, Sandoz, The Menarini Group, ANI Pharmaceuticals, Cumberland Pharmaceuticals, Melinta Therapeutics, Monarch Pharmachem, JHP Pharmaceuticals, NPS Pharmaceuticals, and Xellia Pharmaceuticals. Companies in the Global Peptide Antibiotics Market are adopting several strategic approaches to strengthen their market position and support long-term growth. Major pharmaceutical manufacturers are prioritizing investment in research and development to create advanced antimicrobial compounds capable of addressing drug-resistant infections. Strategic collaborations with biotechnology firms, academic institutions, and research organizations are also helping accelerate drug discovery and clinical development programs. Many companies are expanding their product pipelines by focusing on innovative peptide synthesis technologies and advanced drug delivery systems. In addition, organizations are pursuing regulatory approvals across multiple regions to broaden global market access.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research approach
• 1.3 Quality commitments
  • 1.3.1 GMI AI policy and data integrity commitment
    • 1.3.1.1 Source consistency protocol
• 1.4 Research trail and confidence scoring
  • 1.4.1 Research trail components
  • 1.4.2 Scoring components
• 1.5 Data collection
  • 1.5.1 Partial list of primary sources
• 1.6 Data mining sources
  • 1.6.1 Paid sources
    • 1.6.1.1 Sources, by region
• 1.7 Base estimates and calculations
  • 1.7.1 Revenue share analysis
  • 1.7.2 Base year calculation
• 1.8 Forecast model
• 1.9 Research transparency addendum
  • 1.9.1 Source attribution framework
  • 1.9.2 Quality assurance metrics
  • 1.9.3 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Type trends
  • 2.2.3 Route of administration trends
  • 2.2.4 Distribution channel trends
• 2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of multi-drug resistant (MDR) bacteria
    • 3.2.1.2 Increasing incidence of acute and chronic infectious diseases
    • 3.2.1.3 Technological advancements in peptide synthesis
    • 3.2.1.4 Rising investments in next-generation antimicrobial R&D
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High production costs
    • 3.2.2.2 Limited oral bioavailability
  • 3.2.3 Market opportunities
    • 3.2.3.1 Expansion of peptide-engineered drug delivery systems
    • 3.2.3.2 Growing demand for novel antimicrobial classes for AMR prevention
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape (Driven by Primary Research)
• 3.5 Pipeline analysis
• 3.6 Future market trends (Driven by Primary Research)
• 3.7 Impact of AI and generative AI on the market
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Type, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Ribosomal synthesized peptide antibiotics
• 5.3 Non-ribosomal synthesized peptide antibiotics

Chapter 6 Market Estimates and Forecast, By Indication, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Skin infection
• 6.3 Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP)
• 6.4 Blood stream infections
• 6.5 Other indications

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Injectable
• 7.3 Oral
• 7.4 Topical
• 7.5 Other routes of administration

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Retail pharmacies
• 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Italy
  • 9.3.5 Spain
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 AbbVie
• 10.2 ANI Pharmaceuticals
• 10.3 Cumberland Pharmaceuticals
• 10.4 Eli Lilly and Company
• 10.5 GSK plc
• 10.6 JHP Pharmaceuticals
• 10.7 Merck
• 10.8 Monarch Pharmachem
• 10.9 Melinta Therapeutics
• 10.10 NPS Pharmaceuticals
• 10.11 Pfizer
• 10.12 Sanofi
• 10.13 Sandoz
• 10.14 Teva Pharmaceuticals
• 10.15 The Menarini Group
• 10.16 Xellia Pharmaceutical